Former Deloitte Executive Joins BrainStorm Cell Therapeutics as Independent Director and Chairman of the Audit Committee
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced that Mordechai (Moti) Friedman, CPA, a former Deloitte Brightman Almagor executive and deputy chairman, has been elected as an independent director of the Company. [BrainStorm Cell Therapeutics Inc. Press Release]
MRC-CRM and iCeMS Sign Agreement on Academic Collaboration
The University of Edinburgh’s Medical Research Council Centre for Regenerative Medicine (MRC-CRM) and Kyoto University Institute for Integrated Cell-Material Sciences (iCeMS) signed a memorandum of understanding covering future collaborative research. [MRC Centre for Regenerative Medicine Press Release]
Mesoblast Update on Valeant Proposal to Cephalon
Mesoblast wishes to inform the market that the Board of its strategic partner Cephalon Inc. has rejected the unsolicited proposal from Valeant Pharmaceuticals International Inc. to acquire its issued share capital or certain assets. [Mesoblast Limited Press Release]
Announcing the First Stem Cell Translational Journal
AlphaMed Press announces the launch of a major peer-reviewed journal, STEM CELLS Translational Medicine, answering an acknowledged need within the research and clinical communities for comprehensive coverage of stem cell science, stem cell-based regenerative medicine and tissue engineering, stem cell-based predictive toxicology, and cancer stem cell investigation. [AlphaMed Press Press Release]